Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017

Angela M Parcesepe, Kathryn Lancaster, E Jennifer Edelman, Raquel DeBoni, Jeremy Ross, Lukoye Atwoli, Mpho Tlali, Keri Althoff, Judicaël Tine, Stephany N Duda, C William Wester, Denis Nash, IeDEA Consortium, Angela M Parcesepe, Kathryn Lancaster, E Jennifer Edelman, Raquel DeBoni, Jeremy Ross, Lukoye Atwoli, Mpho Tlali, Keri Althoff, Judicaël Tine, Stephany N Duda, C William Wester, Denis Nash, IeDEA Consortium

Abstract

Background: Substance use is common among people living with HIV and has been associated with suboptimal HIV treatment outcomes. Integrating substance use services into HIV care is a promising strategy to improve patient outcomes.

Methods: We report on substance use education, screening, and referral practices from two surveys of HIV care and treatment sites participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. HIV care and treatment sites participating in IeDEA are primarily public-sector health facilities and include both academic and community-based hospitals and health facilities. A total of 286 sites in 45 countries participated in the 2014-2015 survey and 237 sites in 44 countries participated in the 2017 survey. We compared changes over time for 147 sites that participated in both surveys.

Results: In 2014-2015, most sites (75%) reported providing substance use-related education on-site (i.e., at the HIV clinic or the same health facility). Approximately half reported on-site screening for substance use (52%) or referrals for substance use treatment (51%). In 2017, the proportion of sites providing on-site substance use-related education, screening, or referrals increased by 9%, 16%, and 8%, respectively. In 2017, on-site substance use screening and referral were most commonly reported at sites serving only adults (compared to only children/adolescents or adults and children/adolescents; screening: 86%, 37%, and 59%, respectively; referral: 76%, 47%, and 46%, respectively) and at sites in high-income countries (compared to upper middle income, lower middle income or low-income countries; screening: 89%, 76%, 68%, and 45%, respectively; referral: 82%, 71%, 57%, and 34%, respectively).

Conclusion: Although there have been increases in the proportion of sites reporting substance use education, screening, and referral services across IeDEA sites, gaps persist in the integration of substance use services into HIV care, particularly in relation to screening and referral practices, with reduced availability for children/adolescents and those receiving care within resource-constrained settings.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Geographic distribution of the HIV…
Fig 1. Geographic distribution of the HIV treatment sites from the IeDEA consortium participating in the 2014–2015 and 2017 global site surveys*.
*Image created by the authors in ESRI’s ArcGIS 10.1; no copyrighted material was used [69, 70].
Fig 2. Changes in availability of on-site…
Fig 2. Changes in availability of on-site substance use-related education, screening, and referral at HIV treatment programs participating in the 2014–2015 and 2017 surveys, IeDEA consortium (n = 147).

References

    1. Petoumenos K, Law MG. Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. Curr opin HIV AIDS. 2016;11(5):514–20. 10.1097/COH.0000000000000306
    1. Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015;15:274 10.1186/s12879-015-0969-x
    1. Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions. Alcohol Clin Exp Res. 2016;40(10):2056–72. 10.1111/acer.13204
    1. Paolillo EW, Gongvatana A, Umlauf A, Letendre SL, Moore DJ. At-Risk Alcohol Use is Associated with Antiretroviral Treatment Nonadherence Among Adults Living with HIV/AIDS. Alcohol Clin Exp Res. 2017;41(8):1518–25. 10.1111/acer.13433
    1. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Human Retroviruses. 2010;26(5):511–8.
    1. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depen. 2010;112(3):178–93.
    1. Nash D, Tymejczyk O, Gadisa T, Kulkarni SG, Hoffman S, Yigzaw M, et al. Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013. J Int AIDS Soc. 2016;19(1):20637 10.7448/IAS.19.1.20637
    1. Cook RL, Zhou Z, Kelso-Chichetto NE, Janelle J, Morano JP, Somboonwit C, et al. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study. Addict Sci Clin Pract. 2017;12(1):22 10.1186/s13722-017-0090-0
    1. Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depen. 2016;161:95–103.
    1. Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BDL, et al. Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare. AIDS Behav. 2019;23(1):140–51. 10.1007/s10461-018-2210-6
    1. Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016;30(2):273–91. 10.1097/QAD.0000000000000922
    1. Weinberger AH, Smith PH, Funk AP, Rabin S, Shuter J. Sex Differences in Tobacco Use Among Persons Living With HIV/AIDS: A Systematic Review and Meta-Analysis. J Acquire Immune Deficiency syndromes (1999). 2017;74(4):439–53.
    1. Shirley DK, Kaner RJ, Glesby MJ. Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis. 2013;57(2):275–82. 10.1093/cid/cit207
    1. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013;56(5):727–34. 10.1093/cid/cis933
    1. Deren S, Cortes T, Dickson VV, Guilamo-Ramos V, Han BH, Karpiak S, et al. Substance Use Among Older People Living With HIV: Challenges for Health Care Providers. Front Public Health. 2019;7:94 10.3389/fpubh.2019.00094
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob health. 2017;5(12):e1192–e207. 10.1016/S2214-109X(17)30375-3
    1. UNAIDS. Harm Reducation Saves Lives. 2017.
    1. Hitch AE, Gause NK, Brown JL. Substance Use Screening in HIV Care Settings: a Review and Critique of the Literature. Curr HIV/AIDS Rep. 2019.
    1. United Nations Office on Drugs and Crime. World Drug Report 2018. 2018.
    1. Lemons A, DeGroote N, Perez A, Craw J, Nyaku M, Broz D, et al. Opioid Misuse Among HIV-Positive Adults in Medical Care: Results From the Medical Monitoring Project, 2009–2014. J Acquir Immune Defic Synd. 2019;80(2):127–34.
    1. Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193 10.1186/s12879-015-0913-0
    1. Asher AK, Hahn JA, Couture MC, Maher K, Page K. People who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care. 2013;24(6):e35–44. 10.1016/j.jana.2012.09.003
    1. UNAIDS. The Gap Report. Geneva, Switzerland: UNAIDS; 2014.
    1. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99–106. 10.1007/s11904-010-0043-7
    1. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy. 2010;21(5):347–58. 10.1016/j.drugpo.2009.11.007
    1. Wechsberg WM, van der Horst C, Ndirangu J, Doherty IA, Kline T, Browne FA, et al. Seek, test, treat: substance-using women in the HIV treatment cascade in South Africa. Addict Sci Clin Pract. 2017;12(1):12 10.1186/s13722-017-0077-x
    1. Muth S, Len A, Evans JL, Phou M, Chhit S, Neak Y, et al. HIV treatment cascade among female entertainment and sex workers in Cambodia: impact of amphetamine use and an HIV prevention program. Addict Sci Clin Pract. 2017;12(1):20 10.1186/s13722-017-0085-x
    1. De Boni RB, Shepherd BE, Grinsztejn B, Cesar C, Cortes C, Padgett D, et al. Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. AIDS Behav. 2016;20(11):2692–9. 10.1007/s10461-016-1398-6
    1. De Boni RB, Peratikos MB, Shepherd BE, Grinsztejn B, Cortes C, Padgett D, et al. Is substance use associated with HIV cascade outcomes in Latin America? PloS One. 2018;13(3):e0194228 10.1371/journal.pone.0194228
    1. Oldfield BJ, Munoz N, McGovern MP, Funaro M, Villanueva M, Tetrault JM, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33(5):873–84. 10.1097/QAD.0000000000002125
    1. Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, et al. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS Behav. 2019;23(1):211–21. 10.1007/s10461-018-2241-z
    1. Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, et al. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017;112(6):1036–44. 10.1111/add.13753
    1. Parry CDH, Carney T, Petersen Williams P. Reducing substance use and risky sexual behaviour among drug users in Durban, South Africa: Assessing the impact of community-level risk-reduction interventions. J Social Aspects HIV/AIDS Res Alliance. 2017;14(1):110–7.
    1. Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med. 2014;40(2):43–52. 10.1080/08964289.2013.866540
    1. Kaaya S, Eustache E, Lapidos-Salaiz I, Musisi S, Psaros C, Wissow L. Grand challenges: Improving HIV treatment outcomes by integrating interventions for co-morbid mental illness. PLoS Med. 2013;10(5):e1001447 10.1371/journal.pmed.1001447
    1. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. IntJ Epid. 2012;41(5):1256–64.
    1. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, et al. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epid. 2007;36(5):969–76.
    1. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epid. 2007;36(2):294–301.
    1. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. BMJ Open. 2020;10(5):e035246 10.1136/bmjopen-2019-035246
    1. Fritz CQ, Blevins M, Lindegren ML, Wools-Kaloutsian K, Musick BS, Cornell M, et al. Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. J Int AIDS Soc. 2017;20(1):20933 10.7448/IAS.20.1.20933
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. 10.1016/j.jbi.2008.08.010
    1. Fredericksen RJ, Edwards TC, Merlin JS, Gibbons LE, Rao D, Batey DS, et al. Patient and provider priorities for self-reported domains of HIV clinical care. AIDS Care. 2015;27(10):1255–64. 10.1080/09540121.2015.1050983
    1. Chander G, Monroe AK, Crane HM, Hutton HE, Saag MS, Cropsey K, et al. HIV primary care providers—Screening, knowledge, attitudes and behaviors related to alcohol interventions. Drug Alcohol Depend. 2016;161:59–66. 10.1016/j.drugalcdep.2016.01.015
    1. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, et al. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addict Sci Clin Pract. 2017;12(1):24 10.1186/s13722-017-0088-7
    1. Gwadz M, de Guzman R, Freeman R, Kutnick A, Silverman E, Leonard NR, et al. Exploring How Substance Use Impedes Engagement along the HIV Care Continuum: A Qualitative Study. Front Public Health. 2016;4:62 10.3389/fpubh.2016.00062
    1. Fredericksen R, Crane PK, Tufano J, Ralston J, Schmidt S, Brown T, et al. Integrating a web-based, patient-administered assessment into primary care for HIV-infected adults. J AIDS HIV Research. 2012;4(2):47–55.
    1. Saxena S, Thornicroft G, Knapp M, Whiteford H. Resources for mental health: scarcity, inequity, and inefficiency. Lancet. 2007;370(9590):878–89. 10.1016/S0140-6736(07)61239-2
    1. Lancaster KE, Hetrick A, Jaquet A, Adedimeji A, Atwoli L, Colby DJ, et al. Substance use and universal access to HIV testing and treatment in sub-Saharan Africa: implications and research priorities. J Virus Erad. 2018;4(Suppl 2):26–32.
    1. Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquire Immune Defic Syndr. 2011;56 Suppl 1:S68–75.
    1. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquire Immune Defic Syndr. 2011;56 Suppl 1:S33–8.
    1. Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP. Behavioral Interventions Targeting Alcohol Use Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis. AIDS Behav. 2017;21(Suppl 2):126–43. 10.1007/s10461-017-1886-3
    1. Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. Journal Int AIDS Soc. 2017;20(1):21585.
    1. Aharonovich E, Hatzenbuehler ML, Johnston B, O'Leary A, Morgenstern J, Wainberg ML, et al. A low-cost, sustainable intervention for drinking reduction in the HIV primary care setting. AIDS Care. 2006;18(6):561–8. 10.1080/09540120500264134
    1. Hasin DS, Aharonovich E, O'Leary A, Greenstein E, Pavlicova M, Arunajadai S, et al. Reducing heavy drinking in HIV primary care: a randomized trial of brief intervention, with and without technological enhancement. Addiction. 2013;108(7):1230–40. 10.1111/add.12127
    1. Proeschold-Bell RJ, Heine A, Pence BW, McAdam K, Quinlivan EB. A cross-site, comparative effectiveness study of an integrated HIV and substance use treatment program. AIDS Patient Care STDs. 2010;24(10):651–8. 10.1089/apc.2010.0073
    1. Papas RK, Sidle JE, Gakinya BN, Baliddawa JB, Martino S, Mwaniki MM, et al. Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. Addiction. 2011;106(12):2156–66. 10.1111/j.1360-0443.2011.03518.x
    1. Agabio R, Leggio L. HIV and alcohol use disorder: we cannot ignore the elephant in the room. Lancet HIV. 2019.
    1. Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, et al. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The lancet HIV. 2019.
    1. Patel V, Saxena S, Lund C, Thornicroft G, Baingana F, Bolton P, et al. The Lancet Commission on global mental health and sustainable development. Lancet. 2018;392(10157):1553–98. 10.1016/S0140-6736(18)31612-X
    1. Galarraga O, Gao B, Gakinya BN, Klein DA, Wamai RG, Sidle JE, et al. Task-shifting alcohol interventions for HIV+ persons in Kenya: a cost-benefit analysis. BMC Health Serv Res. 2017;17(1):239 10.1186/s12913-017-2169-4
    1. Beaton A, Shubkin CD, Chapman S. Addressing substance misuse in adolescents: a review of the literature on the screening, brief intervention, and referral to treatment model. Curr Opin Ped. 2016;28(2):258–65.
    1. Harris SK, Herr-Zaya K, Weinstein Z, Whelton K, Perfas F Jr., Castro-Donlan C, et al. Results of a statewide survey of adolescent substance use screening rates and practices in primary care. Subst Abuse. 2012;33(4):321–6.
    1. Lind Bk P, McCarty D P, Gu Y MS, Baker R P, John McConnell K P. Predictors of substance use treatment initiation and engagement among adult and adolescent Medicaid recipients. Subst Abuse. 2019;40(3):285–91.
    1. Elkington KS, Cruz JE, Warne P, Santamaria EK, Dolezal C, Mellins CA. Marijuana Use and Psychiatric Disorders in Perinatally HIV-Exposed Youth: Does HIV Matter? J Ped Psycho. 2016;41(3):277–86.
    1. Gamarel KE, Brown L, Kahler CW, Fernandez MI, Bruce D, Nichols S. Prevalence and correlates of substance use among youth living with HIV in clinical settings. Drug Alcohol Depend. 2016;169:11–8. 10.1016/j.drugalcdep.2016.10.002
    1. Mutumba M, Elkington KS, Bauermeister JA, Bucek A, Dolezal C, Leu CS, et al. Changes in Substance Use Symptoms Across Adolescence in Youth Perinatally Infected with HIV. AIDS Behav. 2017;21(4):1117–28. 10.1007/s10461-016-1468-9
    1. Evangeli M. Mental health and substance use in HIV-infected adolescents. Curr Opin HIV AIDS. 2018;13(3):204–11. 10.1097/COH.0000000000000451
    1. Oldfield BJ, Munoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, et al. "No more falling through the cracks": A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. J Subst Abuse Treat. 2019;97:28–40. 10.1016/j.jsat.2018.11.007
    1. Environmental Systems Research Institute. ArcGIS Desktop: Release 10. Redlands, CA: Environmental Systems Research Institute; 2011.
    1. UNIGIS Geospatial Education Resources, Countries_WGS84. Shapefile.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner